Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Sui wai Ling
CONTACT
Laurens Groenendijk
CONTACT
Lead
Erasmus Medical Center
With
Rationale: 225Ac-PSMA I\&T is a radiopharmaceutical for therapy of prostate cancer. PSMA is overexpressed on prostate cancer cells. Actium-225 is an alpha emitting radionuclide. When PSMA I\&T is labelled with Actium-225, it can be applied as therapy for prostate cancer. Objective: To evaluate the tolerability and safety of 225Ac-PSMA I\&T in patients with metastatic prostate cancer and recommend a dose for further phase 2 studies. Study design: A clinical prospective, single-center, single-arm, phase I dose escalation therapy study. Study population: Up to 30 patients with advanced metastatic castration-resistant prostate cancer (mCRPC). Intervention: Patients with advanced mCRPC will receive therapy with 225Ac-PSMA I\&T. The first dose-level will not exceed 8 megabecquerel (MBq), as this is reported in the literature as a save activity for treatment. A Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) with Gallium-68-PSMA I\&T (68Ga) will be performed to calculate the precise dose-level needed and as a verification the precise dose-level will be compared with the dose-level of 8 MBq. In the first week after therapy, the PET-MRI will be repeated to observe any effects of the alpha radiation on the metastases and observe the potential changes in 68Ga-PSMA I\&T uptake. Eight weeks after the first cycle, patients will receive the second cycle of 225Ac-PSMA I\&T. If no Dose Limiting Toxicity (DLT) occurs, the dose can be increased for the next DL. If a DLT occurs, the cohort will be expanded to 6 patients. After establishing the recommended dose, an expansion cohort will be opened with a total of 12 patients. Main study endpoints: To investigate the safety, tolerability and biochemical effects of 225Ac-PSMA I\&T injected in patients with metastatic prostate cancer. Primary objective: \- To assess the safety and tolerability of 225Ac-PSMA I\&T administered intravenously Secondary objectives: * To predict and calculate the absorbed-dose in critical organs (e.g. salivary glands, kidneys, bone marrow) by 68Ga-PSMA I\&T PET-MRI * To evaluate the effects of the radionuclide therapy on metastases in the days after therapy using 68Ga-PSMA I\&T PET-MRI * To evaluate the biochemical effects of 225Ac-PSMA I\&T therapy in patients with metastatic prostate cancer
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted